Harish Nagaraj, In Charge of the Integrated Molecular Imaging Centre at the Kenyatta University Teaching, Referral, and Research Hospital, shared a post on LinkedIn:
“A Historic Milestone in Cancer Care for Kenya and East Africa
Proud to share that we have successfully performed the first Lutetium-177 PSMA therapy for prostate cancer at a public institution in Kenya and the East African region at the Integrated Molecular Imaging Centre (IMIC), Kenyatta University Teaching, Referral & Research Hospital.
This marks a major leap in “theranostics”, bringing targeted radioligand therapy to patients in a region where access to such advanced care has been limited.
With support from the Ministry of Health, Kenya, Kenyatta University Teaching, Referral & Research Hospital, International Atomic Energy Agency (IAEA), and the Oncidium foundation, this breakthrough showcases what is possible through collaboration, vision, and commitment to equity in cancer care.
This is more than just a treatment, it’s hope delivered through science, and a promise that “precision medicine” can and should reach all corners of the world.
Special thanks to all the staff of Integrated Molecular imaging centre, KUTRRH who contributed to this historic event.”
More from Harish Nagaraj.
